Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001855715 | SCV002294928 | uncertain significance | Ehlers-Danlos syndrome, spondylodysplastic type, 2; Spondyloepimetaphyseal dysplasia with joint laxity | 2021-04-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with B3GALT6-related conditions ‚Äã(PMID: 29931299). ClinVar contains an entry for this variant (Variation ID: 624636) The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the ExAC database. This sequence change replaces tyrosine with cysteine at codon 182 of the B3GALT6 protein (p.Tyr182Cys). The tyrosine residue is highly conserved and there is a large physicochemical difference between tyrosine and cysteine. |
Ce |
RCV003222124 | SCV003916031 | likely pathogenic | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | B3GALT6: PM2, PM3, PS3:Moderate, PP4 |
OMIM | RCV000766204 | SCV000897635 | pathogenic | Ehlers-Danlos syndrome, spondylodysplastic type, 2 | 2019-03-29 | no assertion criteria provided | literature only |